Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval

In Urothelial Carcinoma

 
• By Ayisha Sharma
  
Stamp of approval
The Approval Extends Padcev's Use To The First Line Setting • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip